Ключевые слова:
ген, хронический миелоидный лейкоз, алгоритм диагностики,СЦИ, полимеразная цепная реакция, лечение.Библиографические ссылки
Andrew W. Hil, Melissa J. Perryb, Paul H. Levine Agricultural practices and age of chronic myeloid leukemia diagnosis in India, J. Clinical Epidemiology and Global Health, June 2018? Volume 6, Issue 2, Р. 56–60;
Cross NCP, Ernst T, Branford S, et al. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia. 2023 Nov;37(11):2150–2167. doi: 10.1038/s41375–023–02048–y.
Elias Jabbour, Hagop Kantarjian Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring, ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES, Am J Hematol. 2022; 97:1236–1256;
Farjah H. Algahtani, Fatmah S. Alqahtany Evaluation and characterisation of Chronic myeloid leukemia and various treatments in Saudi Arabia: A retrospective study, Journal of Infection and Public Health,Volume 13, Issue 2, February 2020, P. 295–298;
Guru Subramanian Guru Murthy, How I Manage Patients with Chronic Myeloid Leukemia (CML): Perspectives from Clinical Practice, Blood and Lymphatic Cancer: Targets and Therapy 2022:12 1–6;
Hehlmann R, Lauseker M, Saußele S, et al. Assessment of imatinib as first– line treatment of chronic myeloid leukemia: 10–year survival results of the randomized CML study IV and impact of non–CML determinants. Leukemia. 2017 Nov; 31(11): 2398–2406. doi: 10.1038/leu.2017.253.
Hehlmann R, Voskanyan A, Lauseker M, et al. High–risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia. 2020 Aug; 34(8): 2074–2086. doi: 10.1038/s41 375–020–0826–9. Epub 2020 May 7. Erratum in: Leukemia. 2020 Oct; 34(10): 2823. doi: 10.1038/ s41375–020–01039–7.
Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Apr; 34(4): 966–984. doi: 10.1038/s41375–020–0776–2.
Hoffmann V.S., Baccarani M., Hasford J., et al. Treatment and outcome of 2904 CML patients from the EUTOS population–based registry // Leukemia. Nature Publishing Group, 2017. Vol. 31, № 3. P. 593–601.
ISCN 2020: An International System for Human Cytogenomic Nomenclature (2020). Basel: Karger; 2020.
Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul;36(7):1703–1719. doi: 10.1038/s41375–022–01613–1.
Miller K., Madan K. The new ISCN 2016 // European Cytogeneticists Association Newsletter. – 2016. – Vol. 38. – Р. 15–17.
Sara Benchikh, Amale Bousfha, Adil El Hamouchi et all. Chronic myeloid leukemia: cytogenetics and molecular biology’s part in the comprehension and management of the pathology and treatment evolution, Benchikh et al. Egyptian Journal of Medical Human Genetics (2022) 23:29 https:// doi.org/10.1186/s43042–022–00248–2;
Torii Y, Nanjo K, Toubai T, et al. A unique three–way Philadelphia chromosome variant t(4;9;22)(q21;q34;q11.2) in a newly diagnosed patient with chronic phase chronic myeloid leukemia: a case report and review of the literature. J Med Case Rep. 2021 May 25;15(1):285. doi: 10.1186/s13256–021–02885–4.
Ассесорова Ю.Ю., Каримов Х.Я., Бобоев К.Т. Оценка эффективности и качества выполнения стандартного цитогенетического исследования у больных хроническими миелопролиферативными заболеваниями (Методические рекомендации). – Утверждено МЗ РУз № 8 н–р/1260 от 09.12.2021. –Ташкент, 2021. – 24 с.
Зельцер А.Н., Бурнашева Е.В., Шатохин Ю.В. Молекулярно– генетическая характеристика хронического миелоидного лейкоза // Журнал фундаментальной медицины и биологии. –2016. –№1. –с.4–14. https://oncology– association.ru/wp–content/uploads/2022/04/hroniches-kij–mieloidnyj–lejkoz.pdf
Туркина А.Г., Лазарева О.В., Челышева Е.Ю. и др. Результаты терапии больных хроническим миелолейкозом по данным российской части международного многоцентрового популяционного исследования EUTOS Population–Based Study (EUTOS–PBS). Гематология и трансфузиология. 2019; 64(2): 106–121. https://doi.org/10.35 754/0234–5730–2019–64–2–106–121